Anorectic drugs and valvular heart disease: A biological and clinical perspective

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 1, 1998, Pages 35-41

  Wong, James ^a   Sethu, S ^a   Reddy, K ^a   Klein, Allan L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

ADULT; ANOREXIA; AORTA VALVE REGURGITATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; OBESITY; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TREATMENT OUTCOME; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 2642613684     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.1.35     Document Type: Review

References (28)

1. Connolly HM, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine (reply). N Engl J Med 1997; 337:1775.
2. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144:1143-1148.
3. National prescription audit. Plymouth Meeting, Pa: IMS America, 1997.
4. Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim public health recommendations. MMWR 1997; 46:1061-1066.
5. Kassirer JP, Angell M. Prepublication release of Journal articles (editorial). N Engl J Med 1997; 337:1762-1763.
6. Connolly H, Crary J, McGoon M, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581-588.
7. Mark E, Patalas E, Chang H, Evans R, Kessler S. Fatal pulmonary hypertension associated with short term use of fenfluramine and phentermine. N Engl J Med 1997; 337:602-606.
8. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609-616.
9. Gurtner HP. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bulletin de Physio-Pathologie Respiratoire 1979; 15:897-923.
10. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine (letter). N Engl J Med 1997; 337:635.
11. Reid CL, Gradin JL, Yunis C, Kurosaki T, Flack JM. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population. The CARDIA study (abstract). Circulation 1994; 990:1519.
12. Singh JP, Evans JC, Levy D, et al. Prevalence of valvular regurgitation in a population-based cohort (abstract). Circulation 1997; 96:I-541.
13. Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiography 1990; 3:54-63.
14. Cooperative Agreement Program in Pharmacoepidemiology. Epidemiologic study of valvulopathy with fenfluramine use in an HMO. Cooperative Agreement Program in Pharmacoepidemiology (FDA) 1997.
15. Rasmussen S, Corya BC, Glassman RD. Valvular heart disease associated with fenfluramine-phentermine (letter). N Engl J Med 1997; 337:1773.
16. Kurz X, Van Ermen A. Valvular heart disease associated with fenfluramine-phentermine (letter). N Engl J Med 1997; 337:1772-1773.
17. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10(4):241-323.
18. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790-795.
19. Robertson JI. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs. J Cardiovasc Pharmacol 1991; 17(Suppl 5):S48-S53.
20. Redmon B, Raatz S, Bantle JP. Valvular heart disease associated with fenfluramine-phentermine (letter). N Engl J Med 1997; 337:1773-1774.
21. Chesebro JH, Lam JY, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987; 60:10B-16B.
22. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. AM J Physiol 1994; 266(1Pt1):L46-52.
23. Willerson JT, Eidt JF, McNatt J, et al. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol 1991; 17(6 Suppl B):101B-1108.
24. Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation 1993; 88(4 Pt 1):1588-1601.
25. Wong J, Rauhoft C, Dilley R, Agrotis A, Jennings G, Bobik A. Angiotensin converting enzyme inhibition abolishes medial smooth muscle cell PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries. Relationships to neointima formation. Circulation 1997; 96:1631-1640.
26. Spitzer WO. Valvular heart disease associated with fenfluramine-phentermine (letter). N Engl J Med 1997; 337:1774.
27. Spitz A, Schumacher D, Blank R, et al. Long term pharmacologic treatment of morbid obesity in a community practice. Endocrine Practice 1997; 3:269.
28. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997; 96:358-366.